Sacituzumab govitecan vs docetaxel in patients with mNSCLC non-responsive to last anti-PD-(L)1containing regimen: EVOKE-01
Garassino, M. C. Juan-Vidal, O. Felip, E. Girard, N. Dols, M. C. Haggstrom, D. E. Reinmuth, N. Tiseo, M. Hochmair, M. J. Summers, Yvonne
Garassino, M. C.
Juan-Vidal, O.
Felip, E.
Girard, N.
Dols, M. C.
Haggstrom, D. E.
Reinmuth, N.
Tiseo, M.
Hochmair, M. J.
Summers, Yvonne
Citations
Altmetric:
Abstract
Description
Date
2024
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Garassino MC, Juan-Vidal O, Felip E, Girard N, Dols MC, Haggstrom DE, et al. Sacituzumab Govitecan vs Docetaxel in Patients with mNSCLC Non-responsive to Last Anti-PD-(L)1containing Regimen: EVOKE-01. JOURNAL OF THORACIC ONCOLOGY. 2024 OCT;19(10):S26-S7. PubMed PMID: WOS:001337925600041. English.